Filtered By:
Condition: Atrial Fibrillation
Nutrition: Vitamin A

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 34 results found since Jan 2013.

Risk of Ischemic Stroke, Hemorrhagic Stroke, and All-Cause Mortality in Retinal Vein Occlusion: A Nationwide Population-Based Cohort Study.
Conclusions: People with RVO are at a significantly greater risk of developing stroke, ischemic stroke, and hemorrhagic stroke. However, RVO does not significantly increase the risk of all-cause mortality. PMID: 30271630 [PubMed]
Source: Journal of Ophthalmology - October 3, 2018 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Who Should Rather Undergo Transesophageal Echocardiography to Determine Stroke Etiology: Young or Elderly Stroke Patients?
Conclusions: TEE was highly valuable for determining stroke etiology and influenced individual secondary prevention based on available treatment guidelines and expert opinion in most cases. In young patients the impact of TEE was limited to the detection of septal anomalies. By contrast, in older patients TEE detected high numbers of complex aortic atheroma and potential indicators of paroxysmal atrial fibrillation.
Source: Frontiers in Neurology - December 18, 2020 Category: Neurology Source Type: research

New Standards of Care in Ischemic Stroke
Conclusions: Endovascular therapy is now standard of care for eligible patients with anterior large vessel occlusions. Prolonged cardiac monitoring is recommended for patients with cryptogenic stroke. The novel anticoagulants are an alternative to warfarin in patients with AF.
Source: Journal of Neuro-Ophthalmology - August 17, 2017 Category: Opthalmology Tags: State-of-the-Art Review Source Type: research

Contemporary prevalence of carotid stenosis in patients presenting with ischaemic stroke.
CONCLUSION: Carotid stenosis is common, affecting one in five patients presenting with stroke or TIA. Careful MDT discussion may avoid unnecessary intervention and should be the standard of care. PMID: 30938840 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - April 1, 2019 Category: Surgery Authors: Cheng SF, Brown MM, Simister RJ, Richards T Tags: Br J Surg Source Type: research

Rational clinical approach to transient ischaemic attack, stroke and associated mimics: A retrospective cohort study
CONCLUSIONS: The present study demonstrated that specific clinical features and risk factors were associated with the final diagnosis at TIA clinic. These clinical features may assist with diagnosis of TIA in centres without access to a vascular neurologist.PMID:37190670 | DOI:10.1111/1742-6723.14238
Source: Atherosclerosis - May 16, 2023 Category: Cardiology Authors: Rudy Goh Stephen Bacchi Lydia Lam Timothy Kleinig Jim Jannes Source Type: research

Atrial Fibrillation: An Underestimated Cause of Ischemic Monocular Visual Loss?
Introduction: Atrial fibrillation (AF) is a major cause of ischemic stroke and Transient Ischemic Attack (TIA) and investigation for paroxysmal AF is recommended following an embolic brain event. In contrast, retinal ischemic monocular blindness is traditionally considered most linked to carotid artery disease (CAS) and investigating for AF is less vigilant. We aimed to determine the prevalence of AF in patients with ischemic monocular blindness. Methods: Consecutive records of all patients presenting to a daily TIA clinic with transient or permanent ischemic monocular blindness were reviewed, January 2014-October 2016.
Source: Journal of Stroke and Cerebrovascular Diseases - March 28, 2019 Category: Neurology Authors: Angeliki Zarkali, Suk Fun Cheng, Agnes Dados, Robert Simister, Arvind Chandratheva Source Type: research

Stenosis Length and Degree Interact With the Risk of Cerebrovascular Events Related to Internal Carotid Artery Stenosis
Conclusion: We found a statistically insignificant tendency for the ultrasound-measured length of sICAS<70% to be longer than that of sICAS≥70%. Moreover, the ultrasound-measured length of sICAS<90% was significantly longer than that of sICAS 90%. Among patients with sICAS≥70%, the degree and length of stenosis were inversely correlated. Larger studies are needed before a clinical implication can be drawn from these results. Introduction Internal carotid artery stenosis (ICAS) causes around one-fifth of ischemic cerebrovascular stroke and has the highest risk of early stroke recurrence...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Atrial fibrillation post central retinal artery occlusion:role of implantable loop recorders
ConclusionsPatients with CRAO are at risk for subclinical AF, similar to those with cryptogenic stroke. Long term monitoring to detect AF may lead to changes in pharmacotherapy to reduce the risk for subsequent stroke.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - June 20, 2020 Category: Cardiology Authors: Ryan A. Watson, Jennifer Wellings, Rittu Hingorani, Tingting Zhan, Daniel R. Frisch, Reginald T. Ho, Behzad B. Pavri, Robert C. Sergott, Arnold J. Greenspon Tags: DEVICES Source Type: research

Atrial fibrillation post central retinal artery occlusion: Role of implantable loop recorders
ConclusionsPatients with CRAO are at risk for subclinical AF, similar to those with cryptogenic stroke. Long ‐term monitoring to detect AF may lead to changes in pharmacotherapy to reduce the risk for subsequent stroke.
Source: Pacing and Clinical Electrophysiology : PACE - August 17, 2020 Category: Cardiology Authors: Ryan A. Watson, Jennifer Wellings, Rittu Hingorani, Tingting Zhan, Daniel R. Frisch, Reginald T. Ho, Behzad B. Pavri, Robert C. Sergott, Arnold J. Greenspon Tags: DEVICES Source Type: research

Use of Non-Vitamin  K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
ConclusionsAmong patients with NVAF and six or more comorbid conditions, NOACs were associated with varying risk of stroke/SE and MB compared to warfarin and to each other. Rather than a “one drug fits all” approach, our results may be useful for appropriate OAC treatment for multimorbid patients.
Source: Advances in Therapy - May 7, 2021 Category: Drugs & Pharmacology Source Type: research